Want to see BNR full AI Analyst Report?
Gross Margin by Segment
Reveals profitability across different business segments, highlighting which areas are most efficient and potentially more lucrative for the company.Central Laboratory margins are the strongest and have moved higher into late‑2025, signaling improved pricing power or scale advantages. In‑hospital margins suffered a sharp, likely one‑off collapse at end‑2023 but recovered through 2024–25, suggesting contract normalization or management remediation rather than permanent decline. Pharma R&D is the most volatile but improved significantly in late‑2025, hinting at a better project mix or higher‑margin collaborations. If sustained, these margin gains could drive meaningful operating leverage; watch revenue mix and durability of the in‑hospital recovery.
Date | Central Laboratory Channel | In-hospital Channel | Pharma Research and Development Channel |
|---|---|---|---|
Mar 31, 2026 | 89.00 | 73.00 | 47.00 |
Dec 31, 2025 | 89.00 | 75.00 | 67.00 |
Sep 30, 2025 | 82.00 | 72.00 | 73.00 |
Jun 30, 2025 | 88.00 | 74.00 | 57.00 |
Mar 31, 2025 | 84.00 | 76.00 | 57.00 |
Dec 31, 2024 | 84.00 | 68.00 | 62.00 |
Sep 30, 2024 | 83.00 | 73.00 | 48.00 |
Jun 30, 2024 | 79.00 | 74.00 | 48.00 |
Mar 31, 2024 | 78.00 | 68.00 | 46.00 |
Dec 31, 2023 | 82.00 | 45.00 | 57.00 |